A randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients
Phase 3
- Conditions
- Squamous cell carcinomaBasal cell carcinomaKeratinocyte cancerCancer - Non melanoma skin cancer
- Registration Number
- ACTRN12621001715864
- Lead Sponsor
- niversity of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 146
Inclusion Criteria
Be aged 18 years or older
Have received an organ transplant 12 months ago or earlier
Have had least 1 SCC/BCC in the past 5 years
Have at least 5 keratotic lesions on their face at inclusion
Exclusion Criteria
Are unable to provide informed consent
Are currently receiving sirolimus or everolimus orally
Have a skin cancer on their face requiring treatment
Have an open wound on their face requiring treatment
Are pregnant or planning to become pregnant in the next 6 months
Are medically unstable
Have difficulty understanding and signing the PICF document (are non-English speaking or intellectually impaired)
Non-english speaking patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method